Navigation Links
NxStage Appoints New Member to Its Board of Directors and Announces Resignation of Board Member
Date:10/28/2008

LAWRENCE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the addition of Earl R. Lewis to the Company's Board of Directors and the resignation of Peter P. Phildius from the Board.

"I first want to thank Pete for the contributions he has made to the Company. I have benefited greatly from working closely with him over the last 10 years. We look forward to working with Earl and leveraging his extensive business experience," said Jeff Burbank, Chief Executive Officer of NxStage Medical. "His record of successes with high growth technology companies will be of significant value to us as we continue to expand our business."

Mr. Lewis is the current Chairman, President and CEO of Flir Systems Inc. (NYSE: FLIR), a manufacturer of thermal imaging and infrared camera systems. Previously, he served as CEO and President at Thermo Instrument Systems, Inc. He also served Thermo in various executive capacities, including President and Chief Operating Officer, CEO and President of Thermo Optek Corp., and President of Thermo Jarrell Ash Corp. Mr. Lewis is also a member of the board of directors for Harvard Bio Science and American DG Energy.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the contributions Mr. Lewis will make to NxStage's performance and operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements. Certain factors which may affect future operating results are detailed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the period ending June 30, 2008. In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Contact:

Kristen K. Sheppard, Esq.

VP, Investor Relations

ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage Announces Presentation of Data at the American Society of Nephrologys Renal Week 2008 Annual Meeting
2. NxStage Reports Second Quarter 2008 Financial Results
3. NxStage Announces $43 Million Private Placement of Equity Securities
4. NxStage Medical Reports First Quarter 2008 Results
5. NxStage Announces Supply Agreement With Kawasumi Laboratories for Blood Tubing Sets
6. Tsongas Visits Lawrence-based Medical Device Maker NxStage Medical, Inc.
7. Emil Paganini, MD, Joins NxStage(R) as Critical Care Medical Advisor
8. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
9. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
10. NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
11. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... , ... Ray Insurance Agencies, a Dallas area firm providing asset protection services ... a six month charity event aimed at raising local support and donations that will ... the deadliest diseases in America; more than 7.5 million people die from cancer related ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... clinical trial solutions, today announced the further expansion of its eHealth App ... can leverage as part of Bioclinica’s extensive and growing eHealth platform. Applications ...
(Date:2/21/2017)... Francisco, California (PRWEB) , ... February 21, 2017 ... ... the world with over 50,000 participants. The connected care demonstration spanned multiple ... of the National Coordinator, roughly 30% of providers have no Health Information Exchange ...
(Date:2/21/2017)... ... February 21, 2017 , ... CLICKco LLC, ... announced its products are now available for purchase on RonnieColemanNutrition.com, a popular website ... become popular among health-conscious consumers who love coffee but are looking to add ...
(Date:2/20/2017)... ... 20, 2017 , ... MRI screening improves early diagnosis of breast cancer in ... online in the journal Radiology . , MRI has long been known ... ultrasound. Currently, guidelines reserve breast MRI screening for women who have a strong family ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... , Feb. 21, 2017  International Isotopes Inc. ... a private placement with certain investors for approximately $3.4 ... the Company, Series C Convertible Redeemable Preferred Stock (the ... at an annual rate of 6% and is convertible ... plans to use the proceeds for operating capital, to ...
(Date:2/21/2017)... , February 21, 2017 According to a new ... Systems (Surgical Robots, Rehabilitation Robots, Hospital Robots, Non-invasive Surgery Robots)), Application (Orthopedic, Laparoscopy, ... Continue Reading ... MarketsandMarkets Logo ... This report studies the global ...
(Date:2/21/2017)... Feb. 21, 2017 Research and Markets has announced ... Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , ... are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology: